hVIVO (HVO) Competitors GBX 17.75 -0.05 (-0.28%) As of 02/21/2025 12:35 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlines HVO vs. SLN, PRTC, OXB, HZD, FARN, VRP, ARIX, BVXP, AVCT, and 4BBShould you be buying hVIVO stock or one of its competitors? The main competitors of hVIVO include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), Avacta Group (AVCT), and 4basebio (4BB). These companies are all part of the "biotechnology" industry. hVIVO vs. Silence Therapeutics PureTech Health Oxford Biomedica Horizon Discovery Group plc (HZD.L) Faron Pharmaceuticals Oy Verona Pharma plc (VRP.L) Arix Bioscience Bioventix Avacta Group 4basebio Silence Therapeutics (LON:SLN) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Which has stronger valuation and earnings, SLN or HVO? hVIVO has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics£11.35M0.00N/A-£48.60N/AhVIVO£68.74M1.83£17.84M£2.427.32 Does the media refer more to SLN or HVO? In the previous week, hVIVO's average media sentiment score of 0.32 beat Silence Therapeutics' score of 0.00 indicating that hVIVO is being referred to more favorably in the news media. Company Overall Sentiment Silence Therapeutics Neutral hVIVO Neutral Do institutionals & insiders believe in SLN or HVO? 34.9% of hVIVO shares are owned by institutional investors. 14.0% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor SLN or HVO? Silence Therapeutics received 80 more outperform votes than hVIVO when rated by MarketBeat users. However, 69.89% of users gave hVIVO an outperform vote while only 68.81% of users gave Silence Therapeutics an outperform vote. CompanyUnderperformOutperformSilence TherapeuticsOutperform Votes20368.81% Underperform Votes9231.19% hVIVOOutperform Votes12369.89% Underperform Votes5330.11% Is SLN or HVO more profitable? hVIVO has a net margin of 25.96% compared to Silence Therapeutics' net margin of 0.00%. hVIVO's return on equity of 47.93% beat Silence Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silence TherapeuticsN/A N/A N/A hVIVO 25.96%47.93%11.97% SummaryhVIVO beats Silence Therapeutics on 10 of the 11 factors compared between the two stocks. Get hVIVO News Delivered to You Automatically Sign up to receive the latest news and ratings for HVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HVO vs. The Competition Export to ExcelMetrichVIVOBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£125.60M£117.95M£5.84B£2.64BDividend Yield1.10%3.69%4.75%4.98%P/E Ratio7.323.2026.04162.45Price / Sales1.834,826.69447.46313,322.68Price / Cash4.9413.0138.0128.12Price / Book3.1947.077.645.16Net Income£17.84M-£87.82M£3.18B£5.75B7 Day Performance-1.39%0.34%-2.00%-0.99%1 Month Performance-6.08%3.63%-0.44%-0.80%1 Year Performance-36.61%99.15%16.44%39.55% hVIVO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HVOhVIVON/AGBX 17.75-0.3%N/A-29.0%£125.60M£68.74M7.32N/ASLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech Health2.0093 of 5 starsGBX 146.61+0.4%GBX 455+210.3%-24.1%£440.40M£521,320.79-6.01300News CoverageGap UpOXBOxford Biomedica2.519 of 5 starsGBX 385.50-0.9%GBX 433.33+12.4%+102.0%£409.79M£98.31M-2.86891News CoverageHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416FARNFaron Pharmaceuticals OyN/AGBX 170.20+1.6%N/A+32.3%£228.50MN/A-4.5534VRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919BVXPBioventixN/AGBX 2,888-1.3%N/A-41.7%£151.23M£13.65M18.6812Negative NewsAVCTAvacta GroupN/AGBX 39.80-4.3%N/A-53.9%£151.21M£26.29M-5.121204BB4basebioN/AGBX 1,137.60+1.6%N/A+52.3%£145.73M£311,000.00-1,458.46101 Related Companies and Tools Related Companies SLN Competitors PRTC Competitors OXB Competitors HZD Competitors FARN Competitors VRP Competitors ARIX Competitors BVXP Competitors AVCT Competitors 4BB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:HVO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding hVIVO plc Please log in to your account or sign up in order to add this asset to your watchlist. Share hVIVO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
